Teva Pharmaceuticals agreed to pay more than $200 million in fines and divest a key generic drug treating cholesterol to settle price-fixing charges from the US Department of Justice, the agency ...

Teva is refocusing its efforts on biosimilar medicines and cost-cutting. It's also looking to broaden its pipeline more generally to develop more generics. There hasn't been much in the way of ...

Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, ...

The Federal Trade Commission has opened an investigation into Teva Pharmaceuticals, citing the company’s refusal to take down about two dozen patents for its asthma and COPD inhalers ...

TEL AVIV, Israel and PARSIPPANY, N.J. and REYKJAVIK, Iceland, July 24, 2023 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE ...